Top videos | SnacTube

Home
Articles

Top videos

All Time

Today

This week

This month

This year

टंग कैंसर सर्जरी के बाद आप क्या खा सकते हैं? | Diet after Tongue Cancer Surgery |Dr Amit Chakraborty administrator 20 Views • 2 years ago

In this video, Dr. Amit Chakraborty (Consultant Surgical Oncologist, Head & Neck Cancer Specialist, SSO Hospital) will tell us about diet modifications after tongue cancer surgery.

00:00 Introduction
00:21 When can a person start eating after a tongue cancer surgery?
00:47 What can stage 2/3 tongue cancer patients eat after surgery?

Tongue cancer is a form of cancer that begins in the cells of the tongue. Treatment for tongue cancer typically involves surgery to remove cancer. Chemotherapy, radiation therapy, and targeted drug therapy also may be recommended.

Treatment for advanced tongue cancers can impact your ability to speak and eat.
The stage 1 tongue cancer patients are given food in the form of liquid starting from the first day itself followed by solid food within 2 days. Patients who get stage 2/3 tongue cancer require 30 to 40% of the tongue to be removed. Such patients are given food with the help of rice tubes according to their body requirements.

By the time tongue cancer is diagnosed for many people, it is often already in an advanced stage. As with many cancers, tongue cancer treatment has a greater chance of success if the cancer is caught early.

To know more about head & neck cancer treatments, watch the full video.

More of related videos -
1.क्या Oral cancer केलिए biopsy जरुरी है? | क्या बायोप्सी से कैंसर फैलता है? - https://youtu.be/jqtsCxuAyIE
2. मुह के कैंसर के लिए आयुर्वेदिक इलाज | Ayurvedic Treatment For Oral Cancer - https://youtu.be/whkqMksopGI

---------------------
About Dr. Amit Chakraborty
Dr. Amit Chakraborty is a renowned Surgical Oncologist in Mumbai having experience of 9 years. He is skillful in Head & Neck Cancer patient treatment and had operated on more than 1000 cases. He firmly believes in giving quality care to the patient & better patient outcomes. He has faith in the early detection of cancer so that it gives complete care for better overall survival.

Follow us on :
 Website: http://www.cancersurgeon.co.in/
 Facebook : https://www.facebook.com/AmitsCancerCare/
 Instagram : https://www.instagram.com/amitcancercare/
 LinkedIn’ : https://www.linkedin.com/in/dr....-amit-chakraborty-19

#tonguecancer #dietaftertonguecancersurgery #treatments #advancetreatments #dramitchakraborty #amitcancercare

Nivolumab/Ipilimumab Approved In Europe For Frontline Unresectable Malignant Pleural Mesothelioma administrator 17 Views • 2 years ago

Nivolumab And Ipilimumab Approved In Europe For Frontline Unresectable Malignant Pleural Mesothelioma
➡️ http://MesotheliomaUSA.net

The European Commission has approved the dual immunotherapy combination of nivolumab and ipilimumab for use in the frontline treatment of adults with unresectable malignant pleural mesothelioma.

The regulatory decision was based on findings from the phase 3 CheckMate-743 trial (NCT02899299), which showed that the doublet resulted in a 26% reduction in the risk of death compared with platinum-based, standard-of-care chemotherapy (HR, 0.74; 96.6% CI, 0.60-0.91; P = .002). The median OS with the immunotherapy regimen was 18.1 months (95% CI, 16.8-21.4) vs 14.1 months (95% CI, 12.4-16.2) with chemotherapy, meeting the primary end point of the trial. The 2-year OS rates in the investigative and combination arms were 41% and 27%, respectively.

This is the first positive phase 3 trial of an immunotherapy in the frontline treatment of malignant pleural mesothelioma, according to Bristol Myers Squibb.

“After many years of limited progress in the treatment of malignant mesothelioma, we saw an important clinical benefit for patients with nivolumab plus ipilimumab in the CheckMate-743 trial,” Paul Baas, MD, PhD, of the Department of Thoracic Oncology at the Netherlands Cancer Institute and the University of Leiden, stated in a press release. “With the EC approval of this dual immunotherapy combination, patients and doctors will now have a new treatment option that has shown significant improvements in survival to manage this resistant disease.”

In the open-label, multicenter phase 3 CheckMate-743 trial, investigators examined nivolumab plus ipilimumab vs chemotherapy, which was either pemetrexed and cisplatin or carboplatin, in 605 patients with previously untreated malignant pleural mesothelioma.

Notably, patients who had interstitial lung disease, active autoimmune disease, any conditions that required systemic immunosuppression, or active brain metastases, were not eligible for enrollment. Participants were stratified based on histology, epithelial vs non-epithelial disease, and gender.

Study participants were randomized to receive either nivolumab at 3 mg/kg biweekly plus ipilimumab at 1 mg/kg every 6 weeks (n = 303), or cisplatin at 75 mg/m2 or carboplatin AUC 5 plus pemetrexed at 500 mg/m2 in 21-day treatment cycles for 6 cycles. Patients continued to receive treatment until progressive disease or intolerable toxicity; if in the doublet immunotherapy arm, they received up until 24 months.

The primary end point of the trial was OS in all randomized patients, while other key end points included progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR) per blinded independent central review and RECIST criteria. Other exploratory end points comprised safety, pharmacokinetics, immunogenicity, and patient-reported outcomes.

Additional data from the trial showed that the median PFS with nivolumab plus ipilimumab was shorter than that observed with chemotherapy, at 6.8 months vs 7.2 months, respectively (HR, 1.00; 95% CI, 0.82-1.21). However, the 1-year PFS rates in the investigative and control arms were 30% and 16%, respectively, while the 2-year PFS rates were 24% and 7%, respectively.

The ORRs between the investigative and control arms were similar, at 40% (95% CI, 34.1%-45.4%) and 43% (95% CI, 37.1%-48.5%), respectively. Moreover, the median DOR achieved with the doublet was 11.0 months (95% CI, 8.1-16.5) vs 6.7 months with chemotherapy (95% CI, 5.3-7.1). Thirty-two percent of the responders who received the immunotherapy combination experienced a response that continued at 2 years vs just 8% who received the chemotherapy. The median time to response was 2.7 months with the doublet and 2.5 months with the chemotherapy.

Additional data presented during the 2020 International Association for the Study of Lung Cancer’s World Conference on Lung Cancer Virtual Presidential Symposium showed that the 1-year OS rate with nivolumab plus ipilimumab was 68% vs 58% with chemotherapy. The 2-year OS rates in the investigative and control arms were 41% and 27%, respectively.

Notably, the survival benefit of the dual immunotherapy regimen was observed across all prespecified subgroups, irrespective of epithelioid disease or PD-L1 expression.

Regarding safety, nivolumab plus ipilimumab was determined to be manageable using established adverse effect management protocols.

Nivolumab And Ipilimumab Approved In Europe For Frontline Unresectable Malignant Pleural Mesothelioma
https://www.youtube.com/watch?v=DA_yr5WbOM8
https://www.youtube.com/channe....l/UCOVJwa1zpdmoeq2db

#nivolumab #opdivo #ipilimumab #yervoy #malignant #pleuralmesothelioma #europeancommission #immunotherapy

🔗 https://www.onclive.com/view/n....ivolumab-ipilimumab-

Boozman Secures Improvements in Veterans’ Access to Lifesaving Cancer Screenings administrator 17 Views • 2 years ago

U.S. Senator John Boozman (R-AR), a senior member of the Senate Veterans’ Affairs Committee, highlighted passage of a pair of legislative initiatives he championed to modernize Department of Veterans Affairs (VA) breast cancer screening policies and the delivery of lifesaving care for women veterans. The Senate unanimously advanced the Boozman-led measures in March.

SUBSCRIBE to get the latest updates from Sen. Boozman: https://www.youtube.com/user/BoozmanPressOffice

- Visit his website: https://www.boozman.senate.gov/
- Like Senator John Boozman on Facebook: https://www.facebook.com/JohnBoozman/
- Follow @JohnBoozman on Twitter: https://twitter.com/JohnBoozman
- Follow @JohnBoozman on Instagram: https://www.instagram.com/johnboozman/

John Boozman is Arkansas’s senior U.S. Senator and the dean of the state’s Congressional delegation.

A fifth-generation Arkansan, John was raised in Fort Smith and graduated from Northside High School. He went on to play football for the University of Arkansas Razorbacks while completing his pre-optometry requirements. He graduated from the Southern College of Optometry in 1977 and entered private practice that same year co-founding a family business with his brother that would ultimately become a major provider of eye care to Northwest Arkansas.

Decades of experience as a successful healthcare provider and a small business owner guide John’s approach to governing. He is committed to advocating for economic policies that help Arkansas’s small businesses continue to grow and add jobs to our state’s economy. And since agriculture accounts for nearly one-quarter of Arkansas’s economic activity, John has been a consistent champion for our state’s farmers, ranchers and loggers and was instrumental in the fight for an equitable farm bill.

As the son of an Air Force Master Sergeant, John learned at an early age about the sacrifices of our men and women in uniform, as well as the unique challenges military families face. He brings these values with him to Washington where he is committed to enhancing the quality of life for both our veterans and their families. John has authored provisions to extend successful federal homeless veteran programs, expand treatments for our wounded warriors and modernize educational benefits under the GI Bill.

First elected to the Senate in 2010, John was sworn in for a second term on January 3, 2017. Prior to serving in the Senate, he represented the people of the Third District of Arkansas in the U.S. House of Representatives

John serves on four committees in the 117th Congress:
- Committee on Agriculture, Nutrition, and Forestry (Ranking Member)
- Committee on Appropriations (Ranking Member, Subcommittee on Military Construction, Veterans Affairs and Related Agencies)
- Committee on Environment & Public Works
- Committee on Veterans' Affairs